Cited by 244Epilepsy research and treatmentPharmacological Effects and Toxicity StudiesNeuroscience and Neuropharmacology Research

The DOI matches its Crossref record; 96 of the 98 references it cites were found in a registry or an index.

Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)

Open access

Bialer, Meir, Johannessen, Svein I., Levy, René H., Perucca, Emilio, Tomson, Torbjörn, White, H. Steve·2013·Epilepsy Research

DOI 10.1016/j.eplepsyres.2012.10.001

Open this paper in CoChat — free account Open PDF

Abstract

The Eleventh Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XI, took place in Eilat, Israel from the 6th to 10th of May 2012. About 100 basic scientists, clinical pharmacologists and neurologists from 20 countries attended the conference, whose main themes included "Indications overlapping with epilepsy" and "Securing the successful development of an investigational antiepileptic drug in the current environment". Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 1994. Like the EILAT X report, the current manuscript focuses only on the preclinical and clinical pharmacology of AEDs that are currently in development. These include brivaracetam, 2-deoxy-glucose, ganaxolone, ICA-105665, imepitoin, NAX 801-2, perampanel and other AMPA receptor antagonists, tonabersat, valnoctamide and its homologue sec-propylbutylacetamide (SPD), VX-765 and YK3089. Since the previous Eilat conference, retigabine (ezogabine) has been marketed and four newer AEDs in development (NAX 810-2, SPD, tonabersat and VX-765) are included in this manuscript.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.eplepsyres.2012.10.001

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam
Lynch, B. A., Lambeng, N., Nocka, K., Kensel-Hammes, P., Bajjalieh, S. M., Matagne, A., & Fuks, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308208101 · Cited by 1,610
The neurobiology of antiepileptic drugs
Rogawski, M. A., & Löscher, W. (2004) · Nature reviews. Neuroscience · doi:10.1038/nrn1430 · Cited by 1,243
Endogenous neurosteroids regulate GABAA receptors through two discrete transmembrane sites
Hosie, A. M., Wilkins, M. E., da Silva, H. M. A., & Smart, T. G. (2006) · Nature · doi:10.1038/nature05324 · Cited by 752
Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy
Barton, M. E., Klein, B. D., Wolf, H. H., & White, H. S. (2001) · Epilepsy Research · doi:10.1016/s0920-1211(01)00302-3 · Cited by 614
Self-citation
An update on GABAA receptors
Mehta, A. K., & Ticku, M. K. (1999) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00052-6 · Cited by 613
The role of cytokines in the pathophysiology of epilepsy
Vezzani, A., Balosso, S., & Ravizza, T. (2008) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2008.03.009 · Cited by 564
Key factors in the discovery and development of new antiepileptic drugs
Bialer, M., & White, H. S. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2997 · Cited by 544
Self-citation
The Treatment of Epilepsy
(2004) · Wiley eBooks · doi:10.1002/9780470752463 · Cited by 509
Adjunctive perampanel for refractory partial-onset seizures
French, J. A., Krauss, G. L., Biton, V., Squillacote, D., Yang, H., Laurenza, A., Kumar, D., Rogawski, M. A., Campanille, V., Floridia, J., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182635735 · Cited by 478
Progress report on new antiepileptic drugs: A summary of the Eigth Eilat Conference (EILAT VIII)
Bialer, M., Johannessen, S. I., Kupferberg, H. J., Levy, R. H., Perucca, E., & Tomson, T. (2006) · Epilepsy Research · doi:10.1016/j.eplepsyres.2006.10.008 · Cited by 477
Self-citation

Flagged first, then by citations

Show all 98 references

2 of the 98 references couldn’t be matched to a known paper.

Research works printed but not linked: 13

Biton, 2009, Brivaracetam as adjunctive treatment of refractory partial-onset seizures in adults: results from two randomized, double-blind, placebo-controlled trials, Epilepsia, 50, 106
Brodsky, 2007, Safety and tolerability of brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset seizures, Epilepsia, 48, 342
Kwan, 2009, Safety and tolerability of brivaracetam as adjunctive treatment in adults with refractory epilepsy: randomized, double-blind, placebo-controlled trial, Epilepsia, 50, 107
Niespodziany, 2009, Brivaracetam modulates Na+ currents expressed in a neuroblastoma cell line compared with carbamazepine, Epilepsia, 50, 107
Rostock, 1998, AWD 131-138 is a potential novel anxiolytic without sedation and amnesia: a comparison with diazepam and buspirone, Naunyn-Schmied. Arch. Pharmacol., 358, R68
Sargentini-Maier, 2008, Pharmacokinetics, safety and tolerability of brivaracetam in healthy elderly subjects, Epilepsia, 49, 452
Stafstrom, 2007, 2-Deoxyglucose effects on spatial learning and exploratory behavior in rodents, Epilepsia, 48, 299
Stockis, 2009, Interaction study between brivaracetam and a combination oral contraceptive, Epilepsia, 50, 96
Sutula, 2008, Dose-response and time course of action of disease-modifying effects of 2DG on kindling progression: effectiveness of administration after seizures, Epilepsia, 49, 382
Tober, 1998, AWD 131-138: a derivative of a series of imidazolinones with anticonvulsant activity, Naunyn-Schmied. Arch. Pharmacol., 358, R68
Tober, 1999, Anticonvulsant activity of AWD 131-138 in genetic animal models of epilepsy, Naunyn-Schmied. Arch. Pharmacol., 359, R97
Van Paesschen, 2007, Efficacy and tolerability of 50 and 150mg/day brivaracetam (UCB 34714) as adjunctive treatment in adults with refractory partial onset epilepsy, Epilepsia, 48, 329
Wasterlain, 2009, Short-term and long-term effects of brivaracetam in an animal model of status epilepticus, Epilepsia, 50, 13

Sorted by citations

Items 101–200 of 244

Efficacy, tolerability and safety of add-on third-generation antiseizure medications in treating focal seizures worldwide: a network meta-analysis of randomised, placebo-controlled trials
Chen, Y., Li, W., Lu, C., Gao, X., Song, H., Zhang, Y., Zhao, S., Cai, G., Guo, Q., Zhou, D., et al. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102513 · Cited by 31
Sulfamide derivatives with selective carbonic anhydrase VII inhibitory action
Villalba, M. L., Palestro, P. H., Ceruso, M., Funes, J. L. G., Talevi, A., Bruno‐Blanch, L. E., Supuran, C. T., & Gavernet, L. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.01.012 · Cited by 31
A Biocatalytic Route to the Novel Antiepileptic Drug Brivaracetam
Schülé, A., Merschaert, A., Szczepaniak, C. J., Maréchal, C., Carly, N., O’Rourke, J., & Ates, C. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00094 · Cited by 31
Neurosteroids and Seizure Activity
Miziak, B., Chrościńska–Krawczyk, M., & Czuczwar, S. J. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.541802 · Cited by 31
New drug classes for the treatment of partial onset epilepsy: focus on perampanel
Shih, J. J., Tatum, & Rudzinski, L. A. (2013) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s37317 · Cited by 31
Novel sulfamides and sulfamates derived from amino esters: Synthetic studies and anticonvulsant activity
Villalba, M. L., Enrique, A., Higgs, J., Castaño, R. A., Goicoechea, S., Taborda, F., Gavernet, L., Lick, I. D., Marder, M., & Blanch, L. E. B. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.02.001 · Cited by 30
What New Modeling Approaches Will Help Us Identify Promising Drug Treatments?
Baraban, S. C., & Löscher, W. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-94-017-8914-1_23 · Cited by 30
The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs
Löscher, W., Hoffmann, K., Twele, F., Potschka, H., & Töllner, K. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.09.003 · Cited by 29
Chemical Modulation of Gasdermin-Mediated Pyroptosis and Therapeutic Potential
Ryder, C. B., Kondolf, H. C., O'Keefe, M. E., Zhou, B., & Abbott, D. W. (2021) · Journal of Molecular Biology · doi:10.1016/j.jmb.2021.167183 · Cited by 28
Altered gene expression profile in a mouse model of SCN8A encephalopathy
Sprissler, R. S., Wagnon, J. L., Bunton-Stasyshyn, R. K. A., Meisler, M. H., & Hammer, M. F. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.11.002 · Cited by 31
Cenobamate (YKP3089) and Drug-Resistant Epilepsy: A Review of the Literature
Rissardo, J. P., & Caprara, A. L. F. (2023) · Medicina · doi:10.3390/medicina59081389 · Cited by 28
Imepitoin as novel treatment option for canine idiopathic epilepsy: pharmacokinetics, distribution, and metabolism in dogs
Rundfeldt, C., Gasparic, A., & Właź, P. (2014) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12117 · Cited by 27
Therapeutic Drug Monitoring of Newer Antiepileptic Drugs
McMillin, G. A., & Krasowski, M. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802025-8.00005-2 · Cited by 27
Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS ‐active derivative of valproic acid with low teratogenic potential
Shekh‐Ahmad, T., Hen, N., Yagen, B., McDonough, J. H., Finnell, R. H., Wlodarczyk, B. J., & Bialer, M. (2013) · Epilepsia · doi:10.1111/epi.12480 · Cited by 25
Self-citation
Is Cenobamate the Breakthrough We Have Been Wishing for?
Specchio, N., Pietrafusa, N., & Vigevano, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179339 · Cited by 25
Current and emerging treatments for absence seizures in young patients
Vrielynck, P. (2013) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s30991 · Cited by 25
Understanding the spectrum of temporal lobe epilepsy: contributions for the development of individualized therapies
Coan, A. C., & Cendes, F. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2013.857604 · Cited by 24
Potential role of brivaracetam in pediatric epilepsy
Verrottı, A., Grasso, E. A., Cacciatore, M., Matricardi, S., & Striano, P. (2020) · Acta Neurologica Scandinavica · doi:10.1111/ane.13347 · Cited by 24
Effect of brivaracetam on CYP3A activity, measured by oral midazolam
Stockis, A., Watanabe, S., & Scheen, A. J. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.446 · Cited by 23
Inflammasomes as contributors to periodontal disease
Marchesan, J. T. (2020) · Journal of Periodontology · doi:10.1002/jper.20-0157 · Cited by 23
Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats
Mitsui, K., Niwa, T., Kawahara, Y., Morimoto, N., Ohmoto, K., Kato, M., Yamaura, Y., Yoshimoto, N., Suna, H., & Katsumata, S. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.011 · Cited by 22
Quantitative systems toxicology (QST) reproduces species differences in PF‐04895162 liver safety due to combined mitochondrial and bile acid toxicity
Generaux, G. T., Lakhani, V., Yang, Y., Nadanaciva, S., Qiu, L., Riccardi, K. A., Di, L., Howell, B. A., Siler, S. Q., Watkins, P. B., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.523 · Cited by 22
Comparative teratogenicity analysis of valnoctamide, risperidone, and olanzapine in mice
Wlodarczyk, B. J., Ogle, K., Lin, L. Y., Bialer, M., & Finnell, R. H. (2015) · Bipolar Disorders · doi:10.1111/bdi.12325 · Cited by 21
Self-citation
The potential of sec -butylpropylacetamide (SPD) and valnoctamide and their individual stereoisomers in status epilepticus
Shekh‐Ahmad, T., Mawasi, H., McDonough, J. H., Yagen, B., & Bialer, M. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.04.012 · Cited by 21
Self-citation
Stereoselective Pharmacodynamic and Pharmacokinetic Analysis of sec-Butylpropylacetamide (SPD), a New CNS-Active Derivative of Valproic Acid with Unique Activity against Status Epilepticus
Hen, N., Shekh‐Ahmad, T., Yagen, B., McDonough, J. H., Finnell, R. H., Wlodarczyk, B. J., & Bialer, M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4007565 · Cited by 21
Self-citation
VX-765 ameliorates inflammation and extracellular matrix accumulation by inhibiting the NOX1/ROS/NF-κB pathway in diabetic nephropathy
Wang, X., Wu, T.-S., Ma, H., Huang, X., Huang, K., Ye, C., & Zhu, S. (2021) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgab112 · Cited by 20
Galanin analogs prevent mortality from seizure-induced respiratory arrest in mice
Collard, R., Aziz, M. C., Rapp, K. D., Cutshall, C., Duyvesteyn, E., & Metcalf, C. S. (2022) · Frontiers in Neural Circuits · doi:10.3389/fncir.2022.901334 · Cited by 20
Development and Validation of a UHPLC–MS/MS-Based Method to Quantify Cenobamate in Human Plasma Samples
Charlier, B., Coglianese, A., Operto, F. F., Coppola, G., de Grazia, U., Menna, P., Filippelli, A., Piaz, F. D., & Izzo, V. (2022) · Molecules · doi:10.3390/molecules27217325 · Cited by 20
Anticonvulsant effects of cenobamate in chemically and electrically induced seizure models in rodents
Melnick, S. M., Shin, Y., & Glenn, K. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18920 · Cited by 20
TRPV1 channel in the pathophysiology of epilepsy and its potential as a molecular target for the development of new antiseizure drug candidates
Socała, K., Jakubiec, M., Abram, M., Mlost, J., Starowicz, K., Kamiński, R. M., Ciepiela, K., Andres‐Mach, M., Zagaja, M. P., Metcalf, C. S., et al. (2024) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2024.102634 · Cited by 23
The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model
Bloms-Funke, P., Bankstahl, M., Bankstahl, J., Kneip, C., Schröder, W., & Löscher, W. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108884 · Cited by 19
Preclinical evaluation of intravenous NAX 810‐2, a novel GalR2‐preferring analog, for anticonvulsant efficacy and pharmacokinetics
Metcalf, C. S., Klein, B. D., McDougle, D. R., Zhang, L., Kaufmann, D., Bulaj, G. W., & White, H. S. (2017) · Epilepsia · doi:10.1111/epi.13647 · Cited by 19
Self-citation
Personalized translational epilepsy research — Novel approaches and future perspectives
Bauer, S., van Alphen, N., Becker, A. J., Chiocchetti, A. G., Deichmann, R., Deller, T., Freiman, T. M., Freitag, C. M., Gehrig, J., Hermsen, A., et al. (2017) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2017.06.040 · Cited by 18
A Compared Study of Eicosapentaenoic Acid and Docosahexaenoic Acid in Improving Seizure-Induced Cognitive Deficiency in a Pentylenetetrazol-Kindling Young Mice Model
Yang, Y., Wang, X., Chen, L., Wang, S., Han, J., Wang, Z., & Wen, M. (2023) · Marine Drugs · doi:10.3390/md21090464 · Cited by 18
Valnoctamide and sec‐butyl‐propylacetamide ( SPD ) for acute seizures and status epilepticus
Shekh‐Ahmad, T., Hen, N., McDonough, J. H., Yagen, B., & Bialer, M. (2013) · Epilepsia · doi:10.1111/epi.12290 · Cited by 18
Self-citation
Pharmacological profile of a 17β-heteroaryl-substituted neuroactive steroid
Hogenkamp, D. J., Tran, M. B., Yoshimura, R. F., Johnstone, T. B. C., Kanner, R., & Gee, K. W. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3494-5 · Cited by 18
Inflammasome Caspase-1 Activity is Elevated in Cerebrospinal Fluid After Aneurysmal Subarachnoid Hemorrhage and Predicts Functional Outcome
Hirsch, Y., Geraghty, J. R., Katz, E. A., & Testai, F. D. (2020) · Neurocritical Care · doi:10.1007/s12028-020-01113-z · Cited by 18
Pyroptosis in Alzheimer’s Disease: Mechanisms and Therapeutic Potential
Tang, T. (2025) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-025-01579-5 · Cited by 17
The Pro‐inflammatory Cytokine Interleukin‐1β is a Key Regulatory Factor for the Postictal Suppression in Mice
Tao, A., Xu, Z., Chen, B., Wang, Y., Wu, X., Zhang, J., Tang, Y., Xu, C., Zhao, H., Hu, W., et al. (2015) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12416 · Cited by 17
Adjunctive cenobamate for the treatment of focal onset seizures in adults with epilepsy: a critical review
Wheless, J. W. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1834855 · Cited by 17
Anticonvulsant potencies of the enantiomers of the neurosteroids androsterone and etiocholanolone exceed those of the natural forms
Żółkowska, D., Dhir, A., Krishnan, K., Covey, D. F., & Rogawski, M. A. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3546-x · Cited by 16
Cognitive and behavioral effects of the anti-epileptic drug cenobamate (YKP3089) and underlying synaptic and cellular mechanisms
Song, W. S., Cho, Y. S., Oh, S. P., Yoon, S. H., Kim, Y. S., & Kim, M. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109292 · Cited by 16
Use of cenobamate for the treatment of focal epilepsy: an Italian expert opinion paper
Villani, F. S., Cianci, V., Bonaventura, C. D., Gennaro, G. D., Galimberti, C. A., Guerrini, R., Neve, A. L., Mecarelli, O., Pietrafusa, N., Specchio, N., et al. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2171291 · Cited by 16
Self-citation
Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate–A national approach to the evaluation of therapeutic drug monitoring data and clinical outcome
Svendsen, T., Brodtkorb, E., Reimers, A., Molden, E., Sætre, E., Johannessen, S. I., & Landmark, C. J. (2016) · Epilepsy Research · doi:10.1016/j.eplepsyres.2016.12.001 · Cited by 16
Self-citation
Investigating psychotropic properties of antiepileptic drugs
Mula, M. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.57 · Cited by 15
Potassium Channel Activator Attenuates Salicylate-Induced Cochlear Hearing Loss Potentially Ameliorating Tinnitus
Sun, W., Liu, J., Zhang, C., Zhou, N., Manohar, S., Winchester, W. J., Miranda, J. A., & Salvi, R. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00077 · Cited by 15
Brivaracetam for the treatment of epilepsy in adults
Mula, M. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.896200 · Cited by 15
Metabolism-based drug discovery in zebrafish: An emerging strategy to uncover new anti-seizure therapies
Ibhazehiebo, K., Rho, J. M., & Kurrasch, D. M. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107988 · Cited by 16
Astroglial connexins in epileptogenesis
Yang, T., Qian, F., Liu, L., Peng, X., Huang, J., Ren, B., & Tang, F.-R. (2020) · Seizure · doi:10.1016/j.seizure.2020.11.022 · Cited by 15
Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019
Scott, T., Qin, C. X., Drummond, G. R., Hobbs, A. J., & Kemp‐Harper, B. K. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.14525 · Cited by 15
IL-1β and HMGB1 in Epileptogenesis: Recent Advances and Clinical Translation
Geng, H., Sha, L., & Chen, L. (2025) · Pharmaceuticals · doi:10.3390/ph18101522 · Cited by 14
Differential Action of Connexin Hemichannel and Pannexin Channel Therapeutics for Potential Treatment of Retinal Diseases
Nor, M. N. M., Rupenthal, I. D., Green, C. R., & Acosta, M. L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041755 · Cited by 14
In silico screening for clinical efficacy of antiseizure medications: Not all central nervous system drugs are alike
Hamed, R., Eyal, A. D., Berman, E., & Eyal, S. (2022) · Epilepsia · doi:10.1111/epi.17479 · Cited by 13
Comparative efficacy of valnoctamide and sec‐butylpropylacetamide ( SPD ) in terminating nerve agent–induced seizures in pediatric rats
Haines, K. M., Matson, L. M., Dunn, E., Ardinger, C. E., Lee‐Stubbs, R. B., Bibi, D., McDonough, J. H., & Bialer, M. (2019) · Epilepsia · doi:10.1111/epi.14630 · Cited by 13
Self-citation
Phase I study of PF‐04895162, a Kv7 channel opener, reveals unexpected hepatotoxicity in healthy subjects, but not rats or monkeys: clinical evidence of disrupted bile acid homeostasis
Aleo, M. D., Aubrecht, J., Bonin, P. D., Burt, D. A., Colangelo, J. L., Luo, L., Schomaker, S., Swiss, R. L., Kirby, S., Rigdon, G. C., et al. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.467 · Cited by 12
Efficacy and safety of cenobamate in patients with uncontrolled focal seizures: A meta‐analysis
Zhang, L., Wang, J., & Wang, C. (2021) · Acta Neurologica Scandinavica · doi:10.1111/ane.13422 · Cited by 12
Immunosenescence of brain accelerates Alzheimer’s disease progression
Chen, H.-Y., Zhao, Y. G., & Xie, Y. (2022) · Reviews in the Neurosciences · doi:10.1515/revneuro-2022-0021 · Cited by 12
Exploring novel AEDs from drugs used for treatment of non-epileptic disorders
Du, C., Zheng, F., & Wang, X. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1158101 · Cited by 12
Cenobamate in Real‐Word Scenario: Results on Efficacy, Side Effects, and Retention Rate in a Single Center Retrospective Study
Badr, M., Helmstaedter, C., Moskau‐Hartmann, S., Pukropski, J., Witt, J., Rüber, T., Dague, K. O., Baumgartner, T. R., Rademacher, M., Surges, R., et al. (2025) · Brain and Behavior · doi:10.1002/brb3.70567 · Cited by 11
Pharmacodynamic and pharmacokinetic analysis of CNS-active constitutional isomers of valnoctamide and sec-butylpropylacetamide — Amide derivatives of valproic acid
Mawasi, H., Shekh‐Ahmad, T., Finnell, R. H., Wlodarczyk, B. J., & Bialer, M. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.02.040 · Cited by 11
Self-citation
Recent treatment advances and novel therapeutic approaches in epilepsy
Serrano, E. A., & Kanner, A. M. (2015) · F1000Prime Reports · doi:10.12703/p7-61 · Cited by 11
Long‐term efficacy of imepitoin in the treatment of naive dogs affected by idiopathic epilepsy
Gallucci, A., Gagliardo, T., Menchetti, M., Bianchi, E., Bucci, D., & Gandini, G. (2017) · Veterinary Record · doi:10.1136/vr.104187 · Cited by 11
Cenobamate: Neuroprotective Potential of a New Antiepileptic Drug
Wiciński, M., Puk, O., & Malinowski, B. (2020) · Neurochemical Research · doi:10.1007/s11064-020-03188-8 · Cited by 12
Strategies to Improve the Efficiency of Transplantation with Mesenchymal Stem Cells for the Treatment of Ischemic Stroke: A Review of Recent Progress
Li, Y., Zhong, W., & Tang, X. (2021) · Stem Cells International · doi:10.1155/2021/9929128 · Cited by 12
Untangling the pathomechanisms of temporal lobe epilepsy—The promise of epileptic biomarkers and novel therapeutic approaches
Szilágyi, T., Száva, I., Metz, J., Mihály, I., & Orbán-Kis, K. (2014) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2014.08.004 · Cited by 10
Multicomponent synthesis and anticonvulsant activity of monocyclic 2,6-diketopiperazine derivatives
Dawidowski, M., & Turło, J. (2013) · Medicinal Chemistry Research · doi:10.1007/s00044-013-0800-4 · Cited by 10
Preclinical Analgesic and Safety Evaluation of the GalR2-preferring Analog, NAX 810-2
Metcalf, C. S., Smith, M. D., Klein, B. D., McDougle, D. R., Zhang, L., & Bulaj, G. W. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2229-5 · Cited by 9
Efficacy of retigabine in ameliorating the brain insult following sarin exposure in the rat
Gore, A., Neufeld-Cohen, A., Egoz, I., Baranes, S., Gez, R., Grauer, E., Chapman, S., & Lazar, S. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.114963 · Cited by 9
Aberrant Connection Formation and Glia Involvement in the Progression of Pharmacoresistant Mesial Temporal Lobe Epilepsy
Vega-García, A., Guevara‐Guzmán, R., García-Gómez, O., Feria-Romero, I. A., Fernández‐Valverde, F., Alonso‐Vanegas, M., & Orozco-Suárez, S. A. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220616162739 · Cited by 9
A randomized, double‐blind, placebo‐ and risperidone‐controlled study on valnoctamide for acute mania
Weiser, M., Levi, L. W., Levine, S. Z., Bialer, M., Shekh‐Ahmad, T., Matei, V. P., Tiugan, A., Cirjaliu, D., Sava, C., Sinita, E., et al. (2017) · Bipolar Disorders · doi:10.1111/bdi.12506 · Cited by 9
Self-citation
Cenobamate, a New Promising Antiseizure Medication: Experimental and Clinical Aspects
Błaszczyk, B., Czuczwar, S. J., & Miziak, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313014 · Cited by 8
Stereoselective pharmacokinetic and pharmacodynamic analysis of a CNS-active sulphamoylphenyl carbamate derivative
Bibi, D., Shusterman, B., Nocentini, A., Supuran, C. T., & Bialer, M. (2019) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2019.1612887 · Cited by 8
Self-citation
Hormones and Steroids as Neurotransmitters
Marwein, S., Biswal, S., & Acharya, P. C. (2020) · Springer eBooks · doi:10.1007/978-981-15-3556-7_14 · Cited by 8
Pharmacokinetic–Pharmacodynamic Correlation and Brain Penetration of sec-Butylpropylacetamide, a New CNS Drug Possessing Unique Activity against Status Epilepticus
Mawasi, H., Bibi, D., Shekh‐Ahmad, T., Shaul, C., Blotnick, S., & Bialer, M. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00221 · Cited by 8
Self-citation
Integrating and optimizing tonabersat in standard glioblastoma therapy: A preclinical study
Zoteva, V., Meulenaere, V. D., Vanhove, C., Leybaert, L., Raedt, R., Pieters, L., Vral, A., Boterberg, T., & Deblaere, K. (2024) · PLoS ONE · doi:10.1371/journal.pone.0300552 · Cited by 7
Antiepileptic potential of ganaxolone
Јаnkovic, S., & Lukić, S. (2016) · Vojnosanitetski pregled · doi:10.2298/vsp151221157j · Cited by 7
BIOMOLECULAR MECHANISM OF ANTI EPILEPTIC DRUGS
Husna, M., & Kurniawan, S. N. (2018) · MNJ (Malang Neurology Journal) · doi:10.21776/ub.mnj.2018.004.01.7 · Cited by 7
The potassium channels: Neurobiology and pharmacology of tinnitus
Lai, H., Gao, M., & Yang, H. (2023) · Journal of Neuroscience Research · doi:10.1002/jnr.25281 · Cited by 6
Imaging Brain Inflammation: If We Can See It, Maybe We Can Treat It
French, J. A. (2016) · Epiliepsy currents/Epilepsy currents · doi:10.5698/1535-7597-16.1.24 · Cited by 6
Introduction to the 2nd Meeting on Immunity and Inflammation in Epilepsy ( IIE 2016)
Vezzani, A., & Rüegg, S. J. (2017) · Epilepsia · doi:10.1111/epi.13780 · Cited by 6
Cenobamate for the Treatment of Focal Seizures
Klein, P., Ferrari, L., & Rosenfeld, W. E. (2020) · touchREVIEWS in Neurology · doi:10.17925/usn.2020.16.2.87 · Cited by 6
Designing better trials for epilepsy medications: the challenge of heterogeneity
Friedman, D. J., & French, J. A. (2013) · Clinical Investigation · doi:10.4155/cli.13.77 · Cited by 6
Anti-inflammatory Strategies for Disease Modification
Vezzani, A., Balosso, S., Varvel, N. H., & Dingledine, R. J. (2024) · doi:10.1093/med/9780197549469.003.0074 · Cited by 5
Dual-functional pH-sensitive nanoliposomes modified with CD47 mimicry peptide enhance icariin delivery to attenuate neuroinflammation and oxidative stress in epilepsy
Wang, J., Du, Y., Su, G., Tang, W., Long, X., He, Y., & Feng, L. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.102528 · Cited by 5
GABAA Receptor Genetics and Clinical Pharmacology
Davies, P. A. (2014) · Current anesthesiology reports · doi:10.1007/s40140-013-0046-1 · Cited by 5
Lethal Caspase-1/4-Dependent Injury Occurs in the First Minutes of Coronary Reperfusion and Requires Calpain Activity
Yang, X., Cohen, M. V., Sayner, S., Audia, J. P., & Downey, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043801 · Cited by 5
PRIOR FORECASTING OF EPILEPTIC SEIZURE AND LOCALIZATION OF EPILEPTOGENIC REGION
Sharma, A., Rai, J. K., & Tewari, R. P. (2017) · Biomedical Engineering Applications Basis and Communications · doi:10.4015/s1016237217500120 · Cited by 5
Polymorphs of DP-VPA Solid Solutions and Their Physicochemical Properties
Hao, C., Jin, J., Xiong, J., Yang, Z., Gao, L., Ma, Y., Liu, B., Liu, X., Chen, Y., & Zhang, G. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.03.017 · Cited by 5
The Epilepsy Foundation's 4th Biennial Epilepsy Pipeline Update Conference
French, J. A., Schachter, S. C., Sirven, J., & Porter, R. J. (2015) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2015.02.033 · Cited by 5
Blockade of connexin hemichannels with tonabersat protects against mild hypoxic ischemic brain injury in neonatal rats
McDouall, A., Wassink, G., Ranasinghe, S., Zhou, K. Q., Karunasinghe, R. N., Dean, J. M., & Davidson, J. O. (2023) · Experimental Neurology · doi:10.1016/j.expneurol.2023.114611 · Cited by 4
Valnoctamide, which reduces rat brain arachidonic acid turnover, is a potential non-teratogenic valproate substitute to treat bipolar disorder
Modi, H. R., Ma, K., Chang, L., Chen, M., & Rapoport, S. I. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.04.048 · Cited by 4
Difficult to Treat Depression
Karp, J. F., Brinton, R. D., Fournier, J. C. J., Harding, L., Jha, M. K., Lenze, E. J., Mathew, S. J., Meltzer-Brody, S. E., Mohr, D. C., Riva‐Posse, P., et al. (2024) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.psprmdd2408ah · Cited by 3
Synthesis, Anticonvulsant, Antinociceptive Activity and Preliminary Safety Evaluations of Novel Hybrid Imidazolidine‐2,4‐Dione Derivatives with Morpholine Moiety
Czopek, A., Byrtus, H., Góra, M., Rapacz, A., Sałat, K., Koczurkiewicz, P., Pękala, E., Obniska, J., & Kamiński, K. (2024) · ChemMedChem · doi:10.1002/cmdc.202400612 · Cited by 3
Inhibition of pyroptosis by belnacasan: A potential strategy for mitigating acute lung injury and multiple organ dysfunction
Güneş, A., Gürgen, D. G., Kaplan, A. A., & Keskin, İ. (2025) · Tissue and Cell · doi:10.1016/j.tice.2025.103034 · Cited by 3
Synergistic effects of the galanin analog 810–2 with the antiseizure medication levetiracetam in rodent seizure models
Metcalf, C. S., Gagangras, S., Bulaj, G. W., & White, H. S. (2022) · Epilepsia · doi:10.1111/epi.17420 · Cited by 3
Self-citation
Cell culture and pharmacokinetic evaluation of a solid dosage formulation containing a water-insoluble orphan drug manufactured by FDM-3DP technology
SAYDAM, M., Timur, S. S., Vural, İ., & Takka, S. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122307 · Cited by 3
Propriedades da Camellia sinensis na Odontologia: uma revisão de literatura
Cambuí, G. D. F., Batista, A. W., Palmeira, J. T., Góes, V. N., Oliveira, W. H. M. D. S. L., Sátyro, M. A. D. S. A., Filho, A. A. D. O., Figueiredo, C. H. M. D. C., Guênes, G. M. T., da Penha, E. S., et al. (2020) · Research Society and Development · doi:10.33448/rsd-v9i8.5417 · Cited by 3
Connexin 43 hemichannels mediate spatial and temporal disease spread in ALSPreprint
Almad, A. A., Taga, A., Joseph, J., Welsh, C., Patankar, A. G., Gross, S. K., Richard, J., Pokharel, A., Lillo, M. A., Dastgheyb, R. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.03.14.990747 · Cited by 3
Clinical predictors and concomitant antiseizure medications effects on seizure control in relation to plasma cenobamate concentration: a multicenter retrospective study
Operto, F. F., Izzo, V., Assenza, G., Balsamo, A. C., Canafoglia, L., Irelli, E. C., Coglianese, A., Bonaventura, C. D., Gambardella, A., Liguori, C., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1668382 · Cited by 2
Antiseizure Medications that Did Not Reach the Epilepsy Market: An Assessment of Factors Contributing to Their Failed Clinical Development Over the Last Three Decades
Bialer, M., & Perucca, E. (2026) · Drugs · doi:10.1007/s40265-026-02297-y · Cited by 3
Self-citation

Authors: Bialer, M., Johannessen, S. I., Levy, R. H., Perucca, E., Tomson, T., & White, H. S.
Affiliations: Hebrew University of Jerusalem (IL)
Oslo University Hospital (NO)
University of Washington (US)
University of Pavia (IT)
Karolinska Institutet (SE)
University of Utah (US)
Corresponding author: Bialer, Meir
ORCID: Bialer, Meir
Johannessen, Svein I.
Levy, René H.
Perucca, Emilio
Tomson, Torbjörn
White, H. Steve
Venue: Epilepsy Research
Publisher: Elsevier BV
Published: 2013-01
Volume: 103
Issue: 1
Pages: 2-30
ISSN: 0920-1211 (ISSN-L)
DOI: 10.1016/j.eplepsyres.2012.10.001
OpenAlex: W2203865877
Cited by: 243
References: 98
Citations by year: 2026: 10 · 2025: 12 · 2024: 14 · 2023: 13 · 2022: 20 · 2021: 17 · 2020: 32 · 2019: 12 · 2018: 10 · 2017: 19 · 2016: 17 · 2015: 23 · 2014: 24 · 2013: 20
FWCI: 2.88
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/3.0/ (vor, 196 d)
Locations: Epilepsy Research (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
Funders: National Institutes of Health
UCB Pharma
Topics: Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords: antiepileptic drugs, drug development, preclinical pharmacology, clinical pharmacology, brivaracetam, 2-deoxyglucose, ganaxolone, perampanel, AMPA receptor antagonists, tonabersat, retigabine, ezogabine, VX-765, epilepsy
MeSH terms: Animals, Anticonvulsants, Clinical Trials as Topic, Congresses as Topic, Epilepsy, Humans, Israel, Drugs, Investigational, Research Report

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Progress report on new antiepileptic drugs: A summary of the Eleventh Eilat Conference (EILAT XI)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks